Lumen Biosciences Brian Finrow breaks down Chinas biotech playbook and explores ways the U.S. can adapt it for its own continued success.

Women leaders are driving success in life sciences but remain underrepresented and undervalued. That needs to change, writes ...

Pay close attention to contract language regarding royalties, including when and where patents expire, or pay the price, ...

Believing “good companies are bought, not sold” does not reflect the reality of most life sciences transactions, write ...

Part one of a two-part series on FDA Commissioner Martin Makary, M.D.s comments at the Gailen Forum in New York City on October 30, 2025.

Since clinical trials have become increasingly complex with more data being collected, this consequently puts more pressure on sponsors to improve efficiencies while still maintaining quality.

In a complex global and competitive world, formulating a plan without testing it against likely external reactions is the equivalent of walking into a battlefield without the right weapons or a plan ...

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...

Marc Richards Biotechnology companies often offer a promise of future success, but it can take years to determine whether all the effort (and expense) will translate into returns. Because of the ...

Life Science industry experts from Life Science Leaders editorial advisory board answer your questions ...

In the increasingly complex world of artificial intelligence (AI), the concept of "correct outcomes" takes on a profound and sometimes ambiguous meaning. Although efforts are made to create AI that ...

In the rapidly evolving world of life sciences, companies are constantly seeking ways to optimize their business structures to better navigate the complex landscape of drug development and financing.